Sector revisions Regeneron Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
750.57 ^USD	+0.61%		+0.23%	-2.76%

Apr. 15	Sanofi and Regeneron?s Dupixent approval in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	CI
Apr. 15	Sanofi and Regeneron?S Dupixent Approves in the Eu as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Visibility	Nbr of analysts
REGENERON PHARMACEUTICALS, INC.		28
UCB		20
SAMSUNG BIOLOGICS CO.,LTD.		25
CSL LIMITED		16
BIOGEN INC.		30
MODERNA, INC.		20
INCYTE CORPORATION		22
SWEDISH ORPHAN BIOVITRUM AB		11
BRIDGEBIO PHARMA, INC.		23
ALTEOGEN INC.		4
BIOMARIN PHARMACEUTICAL INC.		23
AXSOME THERAPEUTICS, INC.		21
KRYSTAL BIOTECH, INC.		9
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD	-	1
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-	1
GRIFOLS, S.A.		12
GAN & LEE PHARMACEUTICALS.		1
SHANGHAI RAAS BLOOD PRODUCTS CO., LTD.	-	-
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.		5
Average		15
Weighted average by Cap.		20